Beam Therapeutics Inc (BEAM) Stock: Evaluating the Market Performance

Moreover, the 36-month beta value for BEAM is 1.77. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for BEAM is 67.96M and currently, short sellers hold a 21.07% of that float. On April 03, 2024, BEAM’s average trading volume was 1.37M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

BEAM) stock’s latest price update

Beam Therapeutics Inc (NASDAQ: BEAM) has experienced a decline in its stock price by -6.46 compared to its previous closing price of 32.66. However, the company has seen a fall of -9.32% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-28 that Beam Therapeutics (BEAM) reported earnings 30 days ago. What’s next for the stock?

BEAM’s Market Performance

Beam Therapeutics Inc (BEAM) has experienced a -9.32% fall in stock performance for the past week, with a -23.32% drop in the past month, and a 12.23% rise in the past quarter. The volatility ratio for the week is 4.04%, and the volatility levels for the past 30 days are at 5.51% for BEAM.. The simple moving average for the past 20 days is -13.73% for BEAM’s stock, with a 9.51% simple moving average for the past 200 days.

Analysts’ Opinion of BEAM

Many brokerage firms have already submitted their reports for BEAM stocks, with JP Morgan repeating the rating for BEAM by listing it as a “Overweight.” The predicted price for BEAM in the upcoming period, according to JP Morgan is $40 based on the research report published on January 29, 2024 of the current year 2024.

BofA Securities, on the other hand, stated in their research note that they expect to see BEAM reach a price target of $35. The rating they have provided for BEAM stocks is “Neutral” according to the report published on December 15th, 2023.

Jefferies gave a rating of “Hold” to BEAM, setting the target price at $30 in the report published on December 08th of the previous year.

BEAM Trading at -5.74% from the 50-Day Moving Average

After a stumble in the market that brought BEAM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.28% of loss for the given period.

Volatility was left at 5.51%, however, over the last 30 days, the volatility rate increased by 4.04%, as shares sank -20.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +28.96% upper at present.

During the last 5 trading sessions, BEAM fell by -9.32%, which changed the moving average for the period of 200-days by -9.56% in comparison to the 20-day moving average, which settled at $35.03. In addition, Beam Therapeutics Inc saw 12.23% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BEAM starting from Evans John M., who sale 60,000 shares at the price of $33.86 back on Mar 28 ’24. After this action, Evans John M. now owns 998,262 shares of Beam Therapeutics Inc, valued at $2,031,402 using the latest closing price.

FMR LLC, the See Remark 1 of Beam Therapeutics Inc, sale 900,000 shares at $30.55 during a trade that took place back on Feb 14 ’24, which means that FMR LLC is holding 1,235,511 shares at $27,496,912 based on the most recent closing price.

Stock Fundamentals for BEAM

Current profitability levels for the company are sitting at:

  • -0.47 for the present operating margin
  • 0.93 for the gross margin

The net margin for Beam Therapeutics Inc stands at -0.32. The total capital return value is set at -0.14. Equity return is now at value -15.46, with -9.46 for asset returns.

Based on Beam Therapeutics Inc (BEAM), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -0.86. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -5.1.

Currently, EBITDA for the company is -156.47 million with net debt to EBITDA at 1.54. When we switch over and look at the enterprise to sales, we see a ratio of 5.91. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.89.


To wrap up, the performance of Beam Therapeutics Inc (BEAM) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts